Pfizer, Inc. is the potential investor for Swedish Orphan Biovitrum AB (Sobi), Reuters reported last week.
Sobi develops medications for rare diseases. In its latest filings the company reported a market value of about $4.3 billion, which makes it attractive to large pharmaceutical companies looking to bolster their pipelines.
On April 27, Sobi’s board of directors confirmed a company was in talks to acquire the Swedish firm, but did not disclose any names. Following Sobi’s revelation that day, shares of the company that was founded in 2001 increased 19 percent on the Swedish stock exchange. Sobi has been rumored to have been entertaining suitors for a while.
Pfizer and Sobi have a marketing deal for Sobi’s hemophilia drug ReFactor AF. In addition to the hemophilia drug, Sobi also manufactures arthritis drug Kineret and Orfadin, a drug used to slow the effects of hereditary tyrosinemia type 1.